Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with <em>EGFR</em>-positive non–small cell lung cancer.
Kazuhiko Nakagawa, MD, PhD
Articles by Kazuhiko Nakagawa, MD, PhD
Latest Updated Articles
Osimertinib Improves Survival in EGFR+ NSCLC, Poses New Challenges for ResistancePublished: September 13th 2019 | Updated: